Highest-materiality recent filing
Sera Prognostics appoints Mark Capone to Board of Directors effective July 1, 2026
Mark Capone appointed as Class II director effective July 1, 2026, and to the Compensation Committee.
Sera Prognostics shareholders elect directors Kamdar and Lawrence, ratify E&Y as auditor
Kim Kamdar, Ph.D. elected with 9,749,623 votes for; 3,062,352 withheld; 12,961,228 broker non-votes.
Sera Prognostics director Jeff Elliott resigns ahead of annual meeting
Jeff Elliott notified Board of resignation effective June 4, 2026; not due to any disagreement.
Sera Prognostics Q1 revenue minimal at $14K; PRIME trial shows 56% reduction in early preterm births
Q1 2026 revenue $14,000 vs $38,000 YoY; net loss $8.4M vs $8.2M; operating expenses $9.4M.
Sera Prognostics Q4 net loss $7.9M; PRIME study shows 56% reduction in preterm births <32 wks
Q4 2025 net loss $7.9M vs $8.6M Q4 2024; full-year net loss $31.9M vs $32.9M.
Sera Prognostics posts investor presentation; no material updates disclosed
Presentation posted on Jan 8, 2026; only title slide 'Redefining pregnancy care to reduce preterm birth' available.
PRIME study: PreTRM blood test cuts preterm births <32 wks by 56%, NICU admissions by 20%
Randomized trial of 5,018 women: 56% fewer births <32 wks, 32% fewer <35 wks.
Sera Prognostics announces PRIME preterm-birth study accepted for peer-reviewed publication
PRIME study findings accepted for publication, following late-breaking abstract at SMFM annual meeting in 2025.
Sera Q3 revenue $16k, net loss $7.8M; launches Medicaid pilot in Nevada
Revenue $16k vs $29k YoY; net loss $7.8M vs $7.9M; cash $102.4M funds operations through 2028.
Sera Prognostics posts investor presentation at H.C. Wainwright conference
New investor presentation posted to corporate website on September 5, 2025.
Sera Prognostics Q2 revenue $17K, net loss $8.0M, PreTRM progress
Revenue $17,000 vs $24,000 in Q2 2024; net loss $8.0M vs $8.3M.
Sera Prognostics announces annual meeting results; directors elected, auditor ratified
Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. elected as Class I directors for three-year terms.
Lee Anderson appointed CCO effective May 8, 2025; reports to CEO Zhenya Lindgardt.
Sera Prognostics Q1 revenue $38k, net loss $8.2M; payor discussions advance
Revenue of $38k vs nil in prior year; net loss $8.2M vs $8.1M.
Sera Prognostics Q4 revenue $24k; PRIME study meets primary endpoints; raised $57.5M
Q4 2024 revenue $24,000; net loss $8.6M vs $7.9M prior year.
Sera Prognostics prices $50M public offering of 1.25M shares and 11.25M pre-funded warrants
Offering priced at $4.00 per share of Class A common stock and $3.9999 per pre-funded warrant.
Sera Prognostics terminates unused $50M ATM offering program
No shares of Class A common stock were sold under the ATM offering since its August 2024 inception.
Sera Prognostics PRIME study meets both co-primary endpoints; cash $68.2M
Cash, cash equivalents, and marketable securities were approximately $68.2 million as of December 31, 2024 (preliminary).
Sera Prognostics files 8-K for new investor presentation at J.P. Morgan Healthcare Conference
Company posted updated investor presentation to its website on January 13, 2025.
Sera Prognostics PRIME study topline results published by SMFM
SMFM published an abstract of topline results for the PRIME study on preterm birth risk assessment.
Sera Prognostics Q3 revenue $29k, net loss $7.9M; PRIME study data locked
Revenue fell to $29k from $42k YoY; net loss widened to $7.9M from $7.2M.
Sera Prognostics Q2 2024 net loss narrows to $8.3M; revenue drops to $24k
Q2 2024 revenue was $24,000, down from $123,000 in Q2 2023.
Sera Prognostics annual meeting elects directors, ratifies auditor
Quorum of 20,402,055 shares (64.4% of eligible) present at June 6, 2024 annual meeting.
Sera Prognostics Q1 net loss narrows to $8.1M; net revenue nil after adjustments
Net revenue nil after periodic review of accounting estimates for older tests; gross revenue $39K vs $100K YoY.
Sera Prognostics reports Q4/FY2023 results; DSMB stops PRIME study early for efficacy
DSMB recommended stopping PRIME enrollment after co-primary endpoints met significance at interim analysis; preparing manuscript.
Sera Prognostics amends Baker Bros. director nomination threshold to 19.9%
Amendment No. 2 to Side Letter with Baker Bros. Advisors LP executed Dec 6, 2023.
Sera Prognostics PRIME study meets efficacy endpoint at interim; enrollment stopped
DSMB recommended stopping PRIME study enrollment after one co-primary endpoint met efficacy stopping criteria at interim.
Sera Prognostics Q3 net loss narrows to $7.2M; appoints permanent CEO and CFO
Revenue of $42k vs $87k YoY; net loss $7.2M vs $10.7M in Q3 2022.
Sera Prognostics posts investor presentation; no material details disclosed
New investor presentation posted to corporate website on September 25, 2023.
Sera Q2 revenue $123K, net loss $10.5M; appoints interim CEO and CFO
Revenue $123,000 (Q2 2023) vs $78,000 (Q2 2022), up 58% YoY but still minimal.
Sera Prognostics CMO Michael R. Foley resigns, moves to consulting role
CMO Michael R. Foley resigned effective June 30, 2023.
Shareholders elected Kim Kamdar, Sandra Lawrence, and Ryan Trimble as Class II directors; each received >17M votes for.
Sera Prognostics CFO and CCO depart; interim leadership appointed; commercial restructuring
CFO Jay Moyes resigns effective June 7, 2023; Austin Aerts appointed interim CFO.
CEO Gregory Critchfield to retire June 8; Transition Agreement provides $584K severance plus bonus
Retirement as President, CEO and Chairman effective June 8, 2023.
Sera Prognostics CEO Greg Critchfield to retire June 8; Zhenya Lindgardt named interim CEO
CEO Gregory Critchfield retires after 12 years, effective June 8, 2023; remains on board.
Sera Prognostics Q1 revenue $100K, net loss $10.6M; AVERT trial positive
Revenue $100K, up 163% from $38K in Q1 2022.
Sera Prognostics reports Q4 net loss $9.7M, revenue $65k; positive AVERT PRETERM trial results
Q4 2022 net loss $9.7M vs $12.5M in Q4 2021; revenue $65k vs $26k.
Sera Prognostics has no exposure to Silicon Valley Bank; no cash or banking relationship
Company does not hold any cash at Silicon Valley Bank (SVB).
Sera Prognostics amends Baker Bros. director nomination right; ownership threshold raised to 9.9%
Amendment to Side Letter with Baker Bros. Advisors LP increases ownership threshold for director nomination from 4.0% to 9.9% of outstanding voting power.
Sera Prognostics Q3 2022: Revenue $87k, Net Loss $10.7M; Banner Health contract signed
Q3 revenue $87,000, up from $23,000 YoY; net loss $10.7M vs $9.9M.
Sera Prognostics Q2 net loss widens to $11.5M; cash runway extended to 2026
Revenue of $78K, up from $20K in Q2 2021, but operating expenses rose to $11.8M from $7.4M.
Sera Prognostics fills missing committee assignment for director Lindgardt
Zhenya Lindgardt appointed to compensation committee effective June 27, 2022.
Sera Prognostics adds Director Sandra Lawrence to audit committee
Sandra A.J. Lawrence was appointed to the Board effective November 29, 2021.
Sera Prognostics adds Dr. Jane Barlow to nominating and governance committee
Dr. Jane Barlow appointed to the nominating and governance committee effective June 27, 2022.
Sera Prognostics stockholders elect three Class I directors, ratify EY as auditor
Elected Jane F. Barlow (15,626,263 for), Mansoor R. Mirza (15,256,849 for), Marcus Wilson (15,420,794 for) as Class I directors.
Sera Prognostics Q1 net loss $12.2M; revenue $38k; PreTRM orders rise
Revenue of $38k in Q1 2022 vs $13k in Q1 2021; still minimal.
Sera Prognostics appoints Dr. Jane F. Barlow to Board of Directors
Dr. Jane F. Barlow appointed as Class I Director effective April 11, 2022; term expires at 2022 annual meeting.
Sera Prognostics Q4 2021 revenue $26k, net loss $12.5M; losses widen as commercial ops scale
Q4 2021 revenue rose to $26k from $6k YoY; net loss of $12.5M vs $5.4M.
Sera Prognostics appoints Sandra A.J. Lawrence to Board of Directors
Appointed effective Nov 29, 2021 as Class II director with term expiring at 2023 annual meeting.
Sera Prognostics Q3 net loss widens to $9.9M; cash $82.5M; salesforce scaling to 26 reps
Revenue $23K vs $5K YoY; net loss $9.9M vs $5.1M YoY.
Jeffrey T. Elliott, a member of the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”), notified the Company of his decision to resign from the Board effective as of June 4, 2026
On June 13, 2023, Michael R. Foley, M.D., notified Sera Prognostics, Inc. (the “ Company ”) of his intention to resign from the position of Chief Medical Officer of the Company, effective as of June 30, 2023, and has moved to a consulting role.
Concurrently with Mr. Moyes’s resignation, Austin Aerts, the Company’s current Vice President of Finance and Corporate Controller, was appointed as the interim Chief Financial Officer of the Company, effective June 7, 2023.
On May 22, 2023, Jay Moyes notified Sera Prognostics, Inc. (the “ Company ”) of his intention to resign from the position of Treasurer and Chief Financial Officer of the Company, effective as of June 7, 2023.
On May 24, 2023, Nadia Altomare notified the Company of her intention to resign from the position of Chief Commercial Officer of the Company, effective as of June 9, 2023, and is expected to move to a consulting role to effect a smooth commercial transition.
Gregory C. Critchfield, M.D., M.S. notified the Company of his intention to retire from the position of President and Chief Executive Officer of the Company and Chairman of the Board of Directors, effective as of June 8, 2023
On May 14, 2023, Gregory C. Critchfield, M.D., M. S. notified Sera Prognostics, Inc. (the “ Company ”) of his intention to retire from the position of President and Chief Executive Officer of the Company and Chairman of the Board of Directors (the “ Board ”), effective as of June 8, 2023.
Kim Kamdar, Ph.D., a member of the Board, has been appointed as Chairperson of the Board, effective as of the Retirement Date.
Concurrently with Dr. Critchfield’s retirement, Zhenya Lindgardt, a member of the Board, was appointed as the Interim Chief Executive Officer of the Company, effective June 8, 2023.
On April 11, 2022, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Jane F. Barlow, M.D., MPH, MBA, effective April 11, 2022 (the “Effective Date”), as a director to the Board to serve as a Class I Director with a term expiring at the Company’s 2022 annual meeting of stockholders.
On November 29, 2021, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Sandra A.J. Lawrence, effective November 29, 2021 (the “Effective Date”), as a director to the Board to serve as a Class II Director with a term expiring at the Company’s 2023 annual meeting of stockholders.
On November 8, 2021, the Board of Directors (the “Board”) of Sera Prognostics, Inc. (the “Company”) appointed Evguenia (Zhenya) Lindgardt, effective November 8, 2021 (the “Effective Date”), as a director to the Board to serve as a Class III Director with a term expiring at the Company’s 2024 annual meeting of stockholders.
Max materiality 0.85 · Median 0.55 · Most common event earnings